期刊文献+

慢性阻塞性肺疾病与心血管疾病关系的研究进展 被引量:8

下载PDF
导出
摘要 慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种具有气流受限特征的可以预防和治疗的疾病,气流受限不完全可逆、呈进行性发展,与肺部对香烟烟雾等有害气体或有害颗粒的异常炎症反应有关[1]。COPD的发病率及死亡率很高,严重威胁到人类的健康。COPD主要累及肺脏,但也可引起全身(或称肺外)的不良效应。
作者 靳娜 孙丽蓉
出处 《临床肺科杂志》 2011年第12期1916-1918,共3页 Journal of Clinical Pulmonary Medicine
  • 相关文献

参考文献23

  • 1Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diag- nosis, management, and prevention of chronic obstructive pulmona- ry disease: GOLD Executive Summary[ J]. Am J Respir Crit Care Med, 2007,176:532 - 555.
  • 2Sin DD, Man SFP. Chronic obstructive pulmonary disease: A novel risk factor for cardiovascular disease[ J]. Can J Physiol Pharmacol, 2005,83:8 - 13.
  • 3Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Perma- nente Medical Care Program[ J ]. Chest, 2005,128 : 2068 - 2075.
  • 4Joseph F, Eunme C,Steven MS. Chronic obstructive pulmonary dis- ease as an independent risk factor for cardiovascular morbidity [ J ]. International J of COPD, 2009,4:337 - 349.
  • 5Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients [ ]]. Respir Res, 2003,4:11.
  • 6Kawamura N, Kubota T, Kawano S, et al. Blockade of NF-kappaB improves cardiac function and survival without affecting inflamma- tion in TNF-alpha-induced cardiomyopathy [ J ]. Cardiovasc Res, 2005,66 : 520 - 529.
  • 7Dabek J, Kulach A, Gasior Z. The role of matrix metalloproteinases in acute coronary ayndromes [ J ]. Eur J Intern Med, 2007,18 (6) : 463 - 466.
  • 8李洋,翟震天,秦玲.基质金属蛋白酶及其抑制剂与急性心肌梗死的关系[J].中国实验诊断学,2009,13(8):1038-1040. 被引量:3
  • 9Israel G, Ayala S, David P, et al. Serum Cytokine Tumor Necrosis Factor-Alpha and Interleukin-6 Associated with the severity of Coro- nary Artery Disease: Indicators of an Active Inflammatory Burden [ J~. Original Articles,2008,10:494 - 498.
  • 10Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic infammation: a systematic review and a meta-analysis[ J]. Thorax, 2004,59:574 - 580.

二级参考文献6

  • 1Pollanen PJ, Lehtimaki T, Mikkelsson J, et al. Matrix metalloproteinase3 and 9 gene promoter polymorphisms:joint action of two loci as a risk factor for coronary artery complicated plaques [ J ]. Atherescleresis, 2005,180 (1):73.
  • 2Li YY, McTieman CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metaUoproteinases and their regulators in cardiac matrix remodeling[J]. Cardiovasc Res,2000,46(2):214.
  • 3Blankenberq S, Ruppreeht HJ, PoirierO, et al. Plasma concentrations and genetic variation of matrix metalloproteinase-9 and prognosis of patients with cardiovascular disease[J]. Circulation,2003,107(12) : 1579.
  • 4Hisashi Kai, HisaoI koda, Hida, et al. Peripheral bloods levels of matrix metalloproteinase-9 and-2 are elevated in patients with acute coronary syndromes[ J ]. Am Coll Cardial, 1998,32 (2) : 368.
  • 5Tao ZY, Cavasin MA, Yang F, et al. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infaretion in mice [ J ]. Life Sci, 2004,74 (12) : 1561.
  • 6George SJ. Terapeutic potential of matrix metalloproteinases inhibitors in atherosclerosis[J]. Expert Opin Investig drugs,2000,9(5) :993.

共引文献2

同被引文献114

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部